Skip to main content

Table 3 Characteristics of patients according to the tertiles of the absolute value of the difference between 1 (first acquisition) and the mean value of 3 liver stiffness measurements

From: 2D-shear wave elastography: number of acquisitions can be reduced according to clinical setting

 

Low tertile

Central tertile

High tertile

p

Gender (N = 434)

 Male

81 (28.7%)

97 (34.4%)

104 (36.9%)

0.312

 Female

48 (31.6%)

59 (38.8%)

45 (36.9%)

 

Age (years) (N = 423)

 < 50

69 (35.6%)

76 (39.2%)

49 (25.2%)

< 0.01

 > 50

54 (23.6%)

78 (34.0%)

97 (42.4%)

 

BMI kg/m2 (N = 251)

 < 25

49 (42.6%)

44 (38.3%)

22 (21.7%)

< 0.01

 25–30

10 (12%)

26 (32%)

45 (56%)

 

 ≥ 30

10 (18%)

15 (27%)

30 (55%)

 

AST (IU/L) (N = 397)

 < 50

89 (42.2%)

69 (32.7%)

53 (25.1%)

< 0.01

 ≥ 50

39 (21%)

68 (36.5%)

79 (42.5%)

 

Total bilirubin (µmol/L) (N = 404)

 < 20

109 (38.6%)

109 (38.6%)

64 (22.8%)

< 0.01

 ≥ 20

24 (19.7%)

32 (26.2%)

66 (54.1%)

 

Cause of CLD

 ALD

6 (9.7%)

17 (27.4%)

39 (62.9%)

 

 HBV

60 (56%)

28 (26%)

20 (18%)

 

 HCV

36 (31%)

43 (32%)

37 (32%)

< 0.01

 NAFLD

17 (24.6%)

23 (33.3%)

29 (42%)

 

 Other

31 (32%)

41 (42%)

25 (26%)

 

Fibrosis stage

 F0

37 (51%)

20 (28%)

15 (21%)

 

 F1

46 (44.5%)

45 (44.5%)

12 (11%)

 

 F2

30 (42%)

27 (37%)

15 (21%)

< 0.01

 F3

18 (33%)

20 (37%)

16 (30%)

 

 F4

16 (11%)

44 (29%)

91 (60%)

 

Steatosis (303)

 S0

41 (29.3%)

56 (40.0%)

43 (30.7%)

 

 S1

20 (24.4%)

36 (43.9%)

26 (31.7%)

0.707

 S2

18 (30.0%)

24 (40.0%)

18 (30.0%)

 

 S3

9 (42.9%)

5 (23.8%)

7 (33.3%)

 

First LSM

 < 7.1 kPa

77 (62.6%)

38 (30.9%)

8 (6.5%)

< 0.01

 ≥ 7.1 kPa

70 (21.3%)

118 (35.9%)

141 (42.9%)

 

First LSM

 < 9.2 kPa

114 (54.2%)

73 (34.8%)

23 (11.0%)

< 0.01

 ≥ 9.2 kPa

33 (13.6%)

83 (34.3%)

126 (52.1%)

 

First LSM

 < 13 kPa

128 (46.7%)

106 (38.7%)

40 (14.6%)

< 0.01

 ≥ 13 kPa

19 (10.7%)

50 (28.1%)

109 (61.2%)

 
  1. ALD alcohol-related liver disease, AST aspartate aminotransferase, BMI body mass index, CLD chronic liver disease, HBV hepatitis B virus, HCV hepatitis C virus, LSM liver stiffness measurement, NAFLD nonalcoholic fatty liver disease